Acorda Therapeutics, Inc.

Published Date: 14/06/2011
Category: Therapies & Markets

Research Report Decription

Acorda Therapeutics, Inc. - SWOT, Strategy and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company’s structure, operation, SWOT analysis, product and service offerings, detailed financials, and corporate actions, providing a 360˚ view of the company. Features:

• Detailed information on Acorda Therapeutics, Inc. required for business and competitor intelligence needs
• A study of the major internal and external factors affecting Acorda Therapeutics, Inc. in the form of a SWOT analysis
• An in-depth view of the business model of Acorda Therapeutics, Inc. including a breakdown and examination of key business segments
• Five-year financial information and charts, including balance sheet, income statement, cash flows, market capitalization and multiples, and key ratios for Acorda Therapeutics, Inc.
• Intelligence on Acorda Therapeutics, Inc.nv’s mergers and acquisitions (M&A), strategic partnerships and alliances, capital raising, private equity transactions, and financial and legal advisors
• News about Acorda Therapeutics, Inc., such as business expansion, restructuring, and contract wins
• Large number of easy-to-grasp charts and graphs that present important data and key trends

Key Questions Answered:

• Gain understanding of the Acorda Therapeutics, Inc. and the factors that influence its strategies
• Track strategic initiatives of the company and latest corporate news and actions
• Assess Acorda Therapeutics, Inc. as a prospective partner, vendor or supplier
• Support sales activities by understanding your customers' businesses better
• Stay up to date on Acorda Therapeutics, Inc.’s business structure, strategy and prospects

Companies Mentioned:

Acorda Therapeutics

Paper Highlights:

Acorda Therapeutics (Acorda) is a commercial-stage biotechnology company that develops and market therapies to restore function in persons with spinal cord injury (SCI), multiple sclerosis (MS) and related conditions of the central nervous system (CNS). Acorda's marketed products include Ampyra (dalfampridine), Zanaflex Capsules (tizanidine hydrochloride) and Zanaflex (tizanidine hydrochloride) tablets. The company primarily operates in the US. It is headquartered in Hawthorne, New York, and employed 249 people as of February 2010. The company recorded revenues of $50 million during the financial year (FY) ended December 2009, an increase of 4.7% over FY2008. The operating loss of the company was $81.3 million during FY2009, as compared to the operating loss of $73.4 million in FY2008. The net loss of the company was $83.9 million in FY2009, as compared to the net loss of $74.3 million in FY2008.